Exco InTouch is Named Microsoft Managed Partner within Life Sciences
Strengthened Partnership Facilitates Advancements in Patient Engagement Solutions
(25 June 2012) Exco InTouch, the leading provider of mobile patient engagement, data collection and communication solutions for the pharmaceutical and healthcare sectors, today announced that it has been named a Microsoft Managed Partner. Exco has been recognized by Microsoft’s Life Science team for the company’s unparalleled expertise in managing patients in regulatory and late phase clinical trials, as well as in the emerging mHealth space for marketed drugs.
Exco InTouch was selected based on a number of criteria, including the company’s established track record of providing unique solutions using cutting-edge technologies, in addition to revenue potential and growth. Exco InTouch is a global provider of regulatory compliant, simple and non-intrusive mobile patient communication solutions for clinical, late phase and mHealth studies. This enables sponsors and CROs to find and retain the right patients through engaging interactions and improved patient experience. The Managed Partner program will provide Exco InTouch with valuable resources to accelerate the adoption of its solutions in the life sciences market.
Tim Davis of Exco InTouch said, “Exco InTouch is delighted to be included in the elite group of Microsoft Managed Partners. The early access we will receive to emerging Microsoft technologies, information, tools and support will enable us to develop the most advanced patient engagement solutions to date and our customers can look forward to experiencing these benefits as our partnership with Microsoft continues.”
“As the life sciences industry continues to adapt to increased regulatory standards and a higher volume of patients, new technology solutions have the potential to revolutionize the way we manage these processes,” said Andrea McGonigle, managing director, Microsoft Life Sciences. “Exco InTouch is an example of a partner that can help companies deliver reliable data throughout their clinical and late phase studies in an accessible and user friendly way.”
For further information on the Exco InTouch range of solutions, please call +44 1279 709 040 or +1 877 327 5777 or visit www.excointouch.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
